|Articles|April 3, 2020
EMA Recommendations on Compassionate Use of Remdesivir for COVID-19
Advertisement
During a virtual meeting held on April 2nd, EMA’s human medicines committee gave recommendations on how the investigational antiviral medicine remdesivir should be used for treating coronavirus disease in compassionate use programs.
To read the reccomendations, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
How the NIMBLE Study Supported Adherence With Quarterly Dosing of CemdisiranSeptember 18th 2025
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Phase IV Trial Shows Strong Immune Response from Moderna’s Updated Spikevax Against LP.8.1 Variant of COVID-19
2
Subcutaneous Saphnelo Shows Positive Phase III Results in Systemic Lupus Erythematosus
3
ACT Brief: Policy Shifts, FDA Inspections, and Tariffs Pose New Challenges for Clinical Trials
4
IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
